GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clene Inc (NAS:CLNNW) » Definitions » Short Interest

Clene (CLNNW) Short Interest


View and export this data going back to 2020. Start your Free Trial

What is Clene Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


Competitive Comparison of Clene's Short Interest

For the Biotechnology subindustry, Clene's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clene's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clene's Short Interest distribution charts can be found below:

* The bar in red indicates where Clene's Short Interest falls into.



Clene (CLNNW) Business Description

Traded in Other Exchanges
Address
6550 South Millrock Drive, Suite G50, Salt Lake City, UT, USA, 84121
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. Its reportable segments: (1) the development and commercialization of novel clean-surfaced nanotechnology therapeutics (Drugs, and (2) the development and commercialization of dietary supplements (Supplements).

Clene (CLNNW) Headlines

From GuruFocus

Clene Announces Launch of Proposed Public Offering

By sperokesalga sperokesalga 06-15-2023

Clene Announces Pricing of $40 Million Public Offering

By sperokesalga sperokesalga 06-16-2023